Compare · CLVS vs JNJ
CLVS vs JNJ
Side-by-side comparison of Clovis Oncology Inc. (CLVS) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLVS and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $538.04B, about 2144.8x CLVS ($250.9M).
- JNJ has hit the wire 11 times in the past 4 weeks while CLVS has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 3 for CLVS).
- Company
- Clovis Oncology Inc.
- Johnson & Johnson
- Price
- $0.08-3.54%
- $223.50-0.77%
- Market cap
- $250.9M
- $538.04B
- 1M return
- -
- -2.80%
- 1Y return
- -
- +43.82%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- News (4w)
- 0
- 11
- Recent ratings
- 3
- 25
Clovis Oncology Inc.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/Ã), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, and Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest CLVS
- SEC Form EFFECT filed by Clovis Oncology Inc.
- SEC Form 15-12G filed by Clovis Oncology Inc.
- SEC Form S-8 POS filed by Clovis Oncology Inc.
- SEC Form S-8 POS filed by Clovis Oncology Inc.
- SEC Form S-8 POS filed by Clovis Oncology Inc.
- SEC Form S-8 POS filed by Clovis Oncology Inc.
- SEC Form S-8 POS filed by Clovis Oncology Inc.
- SEC Form S-8 POS filed by Clovis Oncology Inc.
- SEC Form S-8 POS filed by Clovis Oncology Inc.
- SEC Form S-8 POS filed by Clovis Oncology Inc.
Latest JNJ
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target
- Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference